Last reviewed · How we verify
NCT06661993
Alpha-lipoic Acid in Critically Ill Patients With Sepsis
NA trial testing Placebo in Sepsis in 80 participants. Completed in 28 October 2025.
28 October 2025
Quick facts
| Lead sponsor | Damanhour University |
|---|---|
| Phase | NA |
| Status | Completed |
| Study type | INTERVENTIONAL |
| Allocation | randomized |
| Design | parallel |
| Masking | double |
| Primary purpose | supportive care |
| Enrollment | 80 |
| Start date | 15 October 2024 |
| Primary completion | 28 October 2025 |
| Estimated completion | 28 October 2025 |
| Sites | 1 location across Egypt |
Drugs / interventions tested
- Placebo
- Alpha-lipoic acid — full drug profile →
Conditions studied
- Sepsis — all drugs for Sepsis →
Sponsor
Damanhour University
Who can join
Adults 18 to 80, any sex, with Sepsis. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
Evaluate the of effect of alpha-lipoic acid in critically ill septic patients. 80 septic patients will be enrolled from Damanhur National medical institute, and they will be randomized using simple randomization into control group will receive placebo and ALA group will be given 1800 mg orally or via a nasogastric tube of ALA daily for seven days .
Publications & conference data
No peer-reviewed publications indexed yet for this trial. Completed trials usually publish results within 12-18 months.
Verify or expand the search:
- PubMed search for NCT06661993
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other trials of Alpha-lipoic acid
Trials testing the same drug.
- NCT05713799 — Trial of the Combination of Alpha-Lipoic Acid and Mirabegron in Women and in Men With Obesity · Phase 2 · not yet recruiting
- NCT03788759 — Alpha-lipoic Acid Adjunctive Therapy in Schizophrenia · Phase 2, PHASE3 · completed
Other recruiting trials for Sepsis
Currently open trials in the same condition.
- NCT07507877 — Infraclavicular Axillary Vein Collapsibility Index as a Predictor of Fluid Responsiveness · recruiting
- NCT07154615 — Assessing Immune Dysfunction in Sepsis · recruiting
- NCT07419802 — OxiCLEAR (Oxiris Cytokines and Endotoxin Adsorption Rate) Study · recruiting
- NCT07351344 — African Survey on Sepsis Knowledge (ASK) · recruiting
- NCT07448805 — Accuracy and Safety of the Syai Tag System for Continuous Glucose Monitoring in Intensive Internal Care Unit · NA · recruiting
Other Damanhour University trials
Trials by the same sponsor.
- NCT07307911 — Coenzyme Q10 for Neuroprotection in Paclitaxel-Induced Neuropathy · Phase 2 · completed
- NCT07341893 — Sacubitril-valsartan in Patients With Heart Failure. · NA · recruiting
- NCT07063628 — Triglyceride-Glucose Indices and Left Ventricular Speckle Tracking in Predicting Coronary Artery Disease Severity · completed
- NCT06849388 — Effect of HeartMath Intervention on Stress, Emotional Vitality and Sense of Coherence · NA · recruiting
- NCT07179302 — Pre- and Post-TAVI Patient Assessment: Advancing Outcome Precision in Aortic Valve Therapy · completed
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT06661993 (US National Library of Medicine, public domain)
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Damanhour University
- Last refreshed: 3 December 2025
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT06661993.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing